Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

2 papers

Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson’s disease

Concepción García, Cristina Palomo‐Garo, Moisés Garcı́a-Arencibia, Jaime A. Ramos, Roger G. Pertwee, Javier Fernández‐Ruíz
British Journal of Pharmacology Summary & key facts 2011 205 citations

In rats and mice that had brain lesions used to model Parkinson's disease, the plant compound Δ9-THCV reduced movement problems after a single dose and, with repeated dosing, reduced loss of dopamine-producing neurons in the brain region called the substantia nigra. Some effects seem linked to antioxidant actions and, in…

Cannabis and Cannabinoid Research GABA and Rice Research Neuroscience and Neuropharmacology Research

Ibogaine Administration Modifies GDNF and BDNF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits

Marton, Soledad, González, Bruno, Rodríguez-Bottero, Sebastián, et al.
www.frontiersin.org Summary & key facts 2019 65 citations

In this rat study, animals got a single injection of ibogaine at 20 mg/kg or 40 mg/kg and the researchers measured three neurotrophic factors (GDNF, BDNF, NGF) in four brain regions (VTA, prefrontal cortex, nucleus accumbens, substantia nigra) at 3 and 24 hours. The main changes appeared at 24 hours:…

Nerve injury and regeneration Neurotransmitter Receptor Influence on Behavior Psychedelics and Drug Studies
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.